“…Eighteen cases (6%) changed their treatment regimens completely to achieve disease control [ 11 , 12 , 38 , 43 , 45 , 54 – 58 , 60 , 61 ]. Among patients with psoriasis flares who were receiving prior treatment with biological agents, most (43%) were using IL-17 inhibitors [ 12 , 26 , 38 , 49 , 50 , 58 , 61 , 62 ], followed by TNF-α inhibitors (42%) [ 12 , 26 , 38 , 43 , 47 , 49 , 50 , 62 , 63 ], IL-23 inhibitors (10%) [ 12 , 43 , 49 , 50 , 62 ], IL-12/23 inhibitors (4%) [ 38 , 56 , 59 ], and TYK2 inhibitor (1%) [ 40 ]. Secukinumab [ 12 , 38 , 50 , 58 , 61 ] and adalimumab [ 12 , 26 , 38 , 50 ] were the most frequently used biological agents.…”